Results 141 to 150 of about 25,691 (210)

Treatment with Mirvetuximab-Soravtansin-first clinical experience in advanced ovarian cancer in a comprehensive cancer center. [PDF]

Front Oncol
Schwörer I, Huwer S, Rautenberg B, Neubauer J, Juhasz-Böss I, Jung L.   +5 more
europepmc   +1 more source

Management and survival outcomes of desmoplastic small round cell tumor: a retrospective cohort study from a tertiary cancer center. [PDF]

BMC Cancer
Sundaramoorthy S, Abraham G, Narayanan G, Nair SG, Purushothaman PN, Thambi SM, Mathew SP, Philip DSJ, Nair S, Muthukumarasamy T.   +9 more
europepmc   +1 more source

Outcomes and adverse events following intra-arterial chemotherapy for retinoblastoma: A single center study in South India. [PDF]

World J Clin Pediatr
Das A, Saiteja K, Shah PK, Prema S, Narendran V.   +4 more
europepmc   +1 more source

A Critical Analysis of the Impact of Etoposide as a Topoisomerase II Inhibitor in Cervical Cancer Treatment: A Review. [PDF]

Cancer Med
Kotian N, Reddy Y, Pai P, Sundara BK.
europepmc   +1 more source

Recurrent Ewing's Sarcoma of the Chest Wall in an Adolescent Male Patient: A Complex Multimodal Management and Progressive Disease Course. [PDF]

Cureus
AlRefaie AM, Almarwani S, Alshaikh R, Alfattani M.   +3 more
europepmc   +1 more source

Doxorubicin paclitaxel in pretreated advanced small-cell lung cancer: a large real-life retrospective study. [PDF]

Transl Lung Cancer Res
Cheuvart C, Gougis P, Campedel L, Bourrachot C, Rolland Debord C, Abbar B.   +5 more
europepmc   +1 more source

IDeate-Lung02: a Phase 3 study of second-line ifinatamab deruxtecan in patients with relapsed small cell lung cancer. [PDF]

Future Oncol
Owonikoko TK, Byers L, Cheng Y, Hayashi H, Paz-Ares L, Pérol M, Hu H, Qian M, Garcia CR, Godard J, Tang M, Rudin CM.   +11 more
europepmc   +1 more source

Second allogeneic stem cell transplantation for XMEN disease. [PDF]

BMJ Case Rep
Wirk B.
europepmc   +1 more source

Dinutuximab Beta Added to Temozolomide-Based Chemotherapy for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON Immuno Phase II Trial. [PDF]

J Clin Oncol
Gray JC, Weston R, Owens C, Canete A, Gambart M, De Wilde B, Nysom K, van Eijkelenburg N, Ladenstein R, Castellano A, Gerber NU, Marshall LV, Barone G, Rubio-San-Simon A, Ng A, Vaidya S, Gallego S, Makin G, Burke GAA, McCarthy A, Murphy D, Zwaan CM, López-Almaraz R, Jannier S, Thebaud E, Corradini N, Yeomanson D, Howell L, Tweddle DA, Elliott M, Hobin D, Valteau-Couanet D, Schleiermacher G, Chastagner P, Defachelles AS, Brichard B, George S, Chesler L, Laidler J, Firth C, Holt G, Moroz V, Pearson ADJ, Gates S, Wheatley K, Kearns P, Moreno L.   +46 more
europepmc   +1 more source